Cefalexin is indicated for the treah1Jent of respiratory tract infections (RTI's), urinary tract infections (UTl's), skin and soft tissue infections, otitis media and other infections due to sensitive organisms.

Cefalexin capsules are for oral use. Each capsule should be swallowed whole with water.
DOSAGE
Adults
The dosage is 1-4 g daily in divided doses. Most infections will respond to 500 mg every 8 hours. For skin and soft tissue infections, streptococcal pharyngitis and mild uncomplicated UTI's, the usual dosage is 250 mg every 6 hours or 500 mg every 12 hours. For more severe infections or those caused by less susceptible organisms, larger dosages may be needed.
Older people
The dosage is as for adults. The dosage should be reduced if renal function is markedly impaired.
Use in children and adolescents
The usual recommended daily dosage for children is 25-50 mg/kg in divided doses. For skin and soft tissue infections, streptococcal pharyngitis and mild, uncomplicated urinary tract infections, the total daily dose may be divided and administered every 12 hours. For most infections the following schedule is suggested:
children under 5 years:
125 mg every 8 hours
children 5 years and over:
250 mg every 8 hours
In severe infections the dosage may be doubled. In the therapy of otitis media, clinical studies have shown that a dosage of 75-100mg/kg/day in 4 divided doses is required.
In the treatment of beta-haemolytic streptococcal infections, a therapeutic dose should
be administered for at least 10 days.

Cefalexin is contra-indicated in patients with known allergy to the cephalosporin group of antibiotics. Severe systemic infections, which require parenteral cephalosporin treatment, should not be treated orally during the acute stage. Cefalexin is contraindicated in patients with porphyria.

Cefalexin should be given cautiously to patients who have shown hypersensitivity to
other drugs. Cephalosporins should be given with caution to penicillin-sensitive
patients, as there is some evidence of partial cross-allergenicity between the
penicillins and cephalosporins. Patients have had severe reactions (including
anaphylaxis) to both drugs.
Pseudomembranous colitis has been reported with virtually all broad-spectrum
antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is
important, therefore, to consider its diagnosis in patients who develop diarrhoea in
association with the use of antibiotics. Such colitis may range in severity from mild
to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug
discontinuance alone. In moderate to severe cases, appropriate measures should be
taken.
If the patient experiences an allergic reaction cefalexin should be discontinued and
treatment with the appropriate agents initiated.
Prolonged use of cefalexin may result in the overgrowth of non-susceptible
organisms. Careful observation of the patient is essential. If superinfection occurs
during therapy, appropriate measures should be taken.
Cefalexin should be administered with caution in the presence of markedly impaired
renal function as it is excreted mainly by the kidneys. Careful clinical and laboratory
studies should be made because the safe dosage may be lower than that usually
recommended.
Positive direct Coombs' tests have been reported during treatment with cephalosporin
antibiotics. For haematological studies, or in transfusion cross-matching procedures
when antiglobulin tests are performed on the minor side, or in Coombs' testing of
newborns whose mothers have received cephalosporin antibiotics before parturition,
it should be recognised that a positive Coombs' test may be due to the drug.
A false positive reaction for glucose in the urine may occur with Benedict's or
Fehling's solutions or with copper sulphate test tablets. Tests based on glucose
oxidation reactions may be safely used.

As cephalosporins like cefalexin are only active against proliferating microorganisms, they should not be combined with bacteriostatic antibiotics.
Concomitant use of uricosuric drugs (e.g. probenicid) suppresses renal drug elimination. As a result, cefalexin plasma levels are increased and sustained for longer periods.
If associated with highly potent diuretics (ethacrynic acid, furosemide) or other potentially nephrotoxic antibiotics (aminoglycosides, polymyxin, colistin), cephalosprins may show higher nephrotoxicity.
Combined use of cephalosporins and oral anticoagulants may prolong prothrombin time.
Cefalexin may reduce the effects of oral contraceptives.
A potential interaction between cefalexin and metformin may result in an accumulation of metformin and could result in fatal lactic acidosis.
Hypokalaemia has been described in patient taking cytotoxic drugs for leukaemia when they were given gentamicin and cefalexin.

Pregnancy category B
Pregnancy
Although laboratory and clinical studies have shown no evidence of teratogenicity, caution should be exercised when prescribing for the pregnant patient.
Breastfeedings: The excretion of cefalexin in human breast milk increased up to 4 hours following a 500mg dose. The drug reached a maximum level of 4 micrograms/ml, then decreased gradually and had disappeared 8 hours after administration. Caution should be exercised when cefalexin is administered to a nursing woman

There are no effects on ability to drive or to operate machinery.

Side effects of cefalexin include gastro-intestinal disturbances such as nausea, vomiting, diarrhoea and abdominal discomfort. The most common of these effects is diarrhoea, but this is rarely severe enough to warrant cessation of therapy. Dyspepsia has also occurred. Transient hepatitis and cholestatic jaundice have rarely been reported.
Allergic reactions have been reported such as rash, urticaria, angioedema and rarely erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis
(exanthematic necrolysis). These reactions usually subsided upon discontinuation of the drug, although in some cases supportive therapy may be necessary. Anaphylaxis has also been reported.
Other side effects such as genital and anal pruritus, genital candidiasis, vaginitis and vaginal discharge, dizziness, fatigue, headache, agitation, confusion, hallucinations, arthralgia, arthritis and joint disorders have been reported.
As with other cephalosporins interstitial nephritis has rarely been reported.
Eosinophilia, neutropenia, thrombocytopenia, haemolytic anaemia and slight elevations in AST and ALT have been reported.
As with other broad-spectrum antibiotics prolonged use may result in the overgrowth of non-susceptible organisms, e.g. candida. This may present a vulvo-vaginitis.
There is a possibility of development of pseudomembranous colitis and it is therefore important to consider its diagnosis in patients who develop diarrhoea while taking cefalexin. It may range in severity from mild to life threatening with mild case usually responding to cessation of therapy. Appropriate measures should be taken with moderate to severe cases.
To report any side effects:
o National Pharmacovigilance and Drug Safety Centre (NPC)
− Fax: + 966 112057662
− Call NPC at + 966 112038222, Exts: 2317-2356-2353-2354-2334-2340
− Toll free phone: 8002490000
− E-mail: npc.drug@sfda.gov.sa
− Website: www.sfda.gov.sa/npc

Symptoms of oral overdose may include nausea, vomiting, epigastric distress, diarrhoea and haematuria. General management consists of close clinical and laboratory monitoring of haematological, renal and hepatic functions and coagulation status until the patient is stable.
Serum levels of Cefalexin can be considerably reduced by haemodialysis or peritoneal dialysis.
Unless 5 to 10 times the normal total daily dose has been ingested, gastro-intestinal decontamination should not be necessary.
There have been reports of haematuria without impairment of renal function in children accidentally ingesting more than 3.5g of cefalexin in a day. Treatment has been supportive (fluids) and no sequelae have been reported.

ATC code: J01DB01 First generation cephalosporins
Cefalexin is an oral broad-spectrum antibiotic belonging to the group known as cephalosporins. In adequate concentrations it is bactericidal for sensitive proliferating
microorganisms by inhibiting the biosynthesis of the cell wall. It is active against the following pathogens:
Gram Positive
Staphylococci (coagulase positive as well as penicillinase-producing strains), Streptococci, pneumococci, Corynebacterium diphtheriae, Baccillus anthracis, Clostridia, Listeria monocytogenes, Bacillus subtilis and Bacteroides melaninogenicus.
Gram Negative
Escherichia coli, Salmonellae, Shigellae, Neisseria, Proteus mirabilis, Haemophilus influenzae (some strains), Brucellae, Klebsiella species, Treponema pallidum and actinomycetes.

Cefalexin is almost completely absorbed from the gastrointestinal tract and produces peak plasma concentrations about 1 hour after administration.
A dose of 500 mg produces a peak plasma concentration of about 18 μg per ml; doubling the dose doubles the peak concentration. Cefalexin readily diffuses into tissues, including bone, joints and the pericardial as well as pleural cavities. Only 10-15 % of the dose is bound to plasma proteins. Elimination is mainly renal with 80% of the dose, recovered from the urine, therapeutically active, in the first 6 hours. Cefalexin does not enter cerebrospinal fluid in significant quantities. Cefalexin crosses the placenta and small quantities are found in the milk of nursing mothers. Therapeutically effective concentrations may be found in the bile and some may be excreted by this route.
The half-life has been reported to range from 0.5 to 2 hours and this increases with reduced renal function.

None stated.

Magnesium stearate, sodium starch glycolate

None known

36 Months

Store in a dry place. Do not store above 30 °C.

Immediate packaging	Outer packaging
PVC film 160 mm Aluminum foil 150 mm	Cardboard box

Cephadar^® 250 mg capsules are available in packs of 16 (two blisters of 8), 20 (two blisters of 10) and 500 (50 blisters of 10).

Not all pack sizes may be marketed

Any unused product or waste material should be disposed of in accordance with local requirements.